Author:
Lindner Leandro,Vieta Ana,Rodríguez César,Barnadas Agustí,Sánchez-Rovira Pedro,Martín Iker
Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference34 articles.
1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72.
2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–12.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–82.
4. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992;89(10):4285–9.
5. Ficha Técnica de Herceptin®. Ministerio de sanidad y Política Social e Igualdad. Agencia Española de Medicamentos y Productos Sanitarios. Consultado en enero de 2011. Disponible en http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_Product_Information/human/000278/WC500074922.pdf .
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献